Category: Pharma & Biotech

A Provisional Patent Application for Use of Specific Cannabis Strain in Neuropathic Pain Filed With the US Patent Office

VANCOUVER, British Columbia, Nov. 07, 2017 — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent application to US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a specific cannabis strain in neuropathic pain. An acknowledgement letter from the USPTO was received recently which provided a filing number of US 62/558,066 for this application. Neuropathic pain is a chronic pain associated with tissue and nerve fiber damage in conditions such as cancer and diabetes, and it is normally treated with anticonvulsants, antidepressants, anesthetics, and steroids. In 2017, the Global Neuropathic Pain Market Research Report Forecast to 2023 is estimated to be $5.5 billion USD and it is expected to grow to $8.1 billion USD in 2023*. The applicants have demonstrated effectiveness of a strain in a pain situation that is normally refractory to treatment with conventional analgesics. Veritas CEO, Dr. Lui Franciosi stated, “We want to compete in this large market and this patent application is an important research step as part of establishing a patent estate for Cannevert’s cannabis strains with therapeutic potential in pain.” From the Canadian perspective, the current total market for cannabis is $5 billion CAD of which some 20% is medical (CIBC World Markets, 2016**). With Cannevert’s research, Veritas intends to penetrate 2% of this...

Read More

NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings

COSTA MESA, CA — (Marketwired) — 11/06/17 — NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data obtained from the company’s research and development partner, the University of Mississippi (UM), will be presented at upcoming scientific meetings in November. Research under the direction of Dr. Kenneth Sufka (University of Mississippi) utilizing cannabinoid research led by Dr. Mahmoud ElSohly (University of Mississippi and ElSohly Laboratories, Inc.) will be presented on November 12, 2017 during the afternoon session of the Society of Neuroscience annual meeting in Washington D.C. The abstract title is: “Analgesic effects of cannabidiol and a novel cannabidiol analog (NB2111) in a murine model of cisplatin-induced neuropathy: synergistic effects with sub-analgesic doses of morphine.” Data from these experiments highlighted the potential use of a cannabinoid analogue like NB2111 in addressing pain management with a potency that could rival the opioid-based therapeutic of morphine. Ocular-related research using the analogue of CBD (NB2222) will be presented on November 13, 2017 during the afternoon session of the American Association of Pharmaceutical Scientists (AAPS) meeting held in San Diego, CA. The research team headed by Soumyajit Majumdar, PhD, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy at the University will present: “Analogue derivatization of cannabidiol (CBD) for improved ocular permeation: in vitro and in vivo evaluation”. These series of experiments revealed that NB2222...

Read More

Alliance Negotiates Equity Partnership for Licensed Cultivation Facility in City of Long Beach

July 27, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to announce that the Company has entered into negotiations with a private company for an equity partnership for a licensed cultivation facility in the City of Long Beach. The partnership will be for a 100% ownership in a 6000 sq. ft. licensed medical marijuana cultivation building and a 50% or higher ownership of the cultivation business. The intention would then be to add a Manufacturing License which would add an additional valuable revenue stream to the business. This would provide full ownership of the building and two revenue streams while leaving the running of the day-to-day business to the private company team.  Alliance also expects to provide tissue cultured plantlets to the facility and potentially other facilities in California via an “in-house” lab arrangement.  Alliance will be working with a long-time legal contact in California to begin working through the various rules and regulations with regard to foreign ownership of a US cannabis operation. Dennis Petke, Alliance Growers’ President and CEO, commented on the proposed partnership. “We are very excited to have been presented this tremendous opportunity in the heart of the marijuana-friendly state of California, in a location with the stature of The City of Long Beach. The market is making tremendous inroads into the...

Read More

Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017

STAMFORD, Conn., July 27, 2017 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 3, 2017, at 4:30 p.m. ET to report second quarter 2017 financial results and provide a corporate update. To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 57769313. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website beginning approximately two hours after the call. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pruritus and pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 michael@sternir.com MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com Source:...

Read More

Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients

Phase 3 safety extension trial underway STAMFORD, Conn., June 23, 2017 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to I.V. CR845 for the treatment of moderate-to-severe uremic pruritus (UP) in chronic kidney disease (CKD) patients undergoing hemodialysis. “The FDA’s decision to grant Breakthrough Therapy designation is recognition of both the significant unmet medical need among CKD patients with UP and...

Read More

Cannabis Science Invests in the Research and Development of Cannabinoid-Based Medications to Treat COPD and Asthma

IRVINE, CA–(Marketwired – Jun 23, 2017) –  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease (COPD) and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma. “More institutions continue to realize that Cannabis-derived medications are indeed a promising and effective tool to combat pulmonary diseases, and that there is...

Read More